Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,921 GBX | -0.16% | +5.83% | +7.60% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.38% | 5.35B | B+ | ||
+34.00% | 704B | C+ | ||
+26.60% | 577B | B | ||
-7.75% | 348B | C+ | ||
+18.53% | 327B | B- | ||
+4.95% | 288B | C+ | ||
+15.04% | 234B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-4.89% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HIK Stock
- Ratings Hikma Pharmaceuticals PLC